With our patented technologies, surfaces coated with specialised membrane Fc-receptor molecules are used to capture immune complexes formed in vitro. The technologies allow for flexibility in assay design to detect either IgG or IgM antibodies in human or animal sera and enable high specificity and sensitivity through the immune complex detection mechanism.
Our 96-well test-plates have been pre-coated with the specialised capture molecules. The assay is quite simple: A labelled bait antigen is added to the test in the same step as the patient sample, eliminating a typical additional incubation and washing step.
From there, the plate is incubated, washed and then the detection can be carried out directly, using the supplied colorimetric substrate and stopping solution. Reading of the assay result can be done using a standard 450/620 nm plate reader.
To ensure optimal test sensitivity and specificity, our products are developed and validated in cooperation with the Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany and leading research institutes in endemic countries around the globe. By using thoroughly characterised negative control sample sets, reflecting the divergent immunological background in the relevant populations, we identify potential cross-reactivities with co-circulating pathogens and eliminate these early in the development process by combining our patented assay technology with a potent competitor molecule approach. Before final production, the developed assays are further subjected to intensive validation on comprehensive, high-quality patient sample sets to ensure they meet our standards of both analytic and diagnostic sensitivity.
